Filter trials by:

Year

Indication

Phase

Type

Phase: II

A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Healthy Participants ≥ 50 to ≤ 80 Years of Age.

Year: 2023
Type: Vaccine
Phase: II
Indication: Healthy

A Multiple Arm, Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis.

Year: 2022
Type: Musculoskeletal
Phase: II
Indication: Knee Osteoarthritis

A 12 Week Randomized, Double-Blind, Double Dummy, Parallel Group, Active And Placebo-Controlled, Multicenter Study To Assess The Efficacy And Safety Profile Of Pf-06650833 In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate.

Year: 2017
Type: Musculoskeletal
Phase: II
Indication: Rheumatoid Arthritis

A Double-Blind Placebo-Controlled study of the efficacy and safety of the p38 Map kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma.

Year: 2009
Type: Pharmaceutical - Pain
Phase: II
Indication: Neuropathic Pain

A confirmatory, placebo-controlled, randomised, double-blind, single dummy, parallel group, ratio-finding study in constipated pain patients to establish an optimal Hydromorphone – naloxone ratio with an improved bowel function and a comparable analgesic efficacy compared to Hydromorphone alone.

Year: 2011
Type: Pharmaceutical - Pain
Phase: II, III
Indication: Pain - General

A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of topical Lidocaine Spray in Patients with Postherpetic Neuralgia.

Year: 2018
Type: Pharmaceutical - Pain
Phase: II
Indication: Postherpetic Neuralgia

A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 100 mg b.i.d. in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMPADINE).

Year: 2018
Type: Pharmaceutical - Pain
Phase: II
Indication: Painful Diabetic Neuropathy

Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Participants with Active Rheumatoid Arthritis despite Ongoing Methotrexate Therapy.

Year: 2010
Type: Musculoskeletal
Phase: II
Indication: Rheumatoid Arthritis

A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Parallel Group Exploratory Study to Investigate the Efficacy, Safety and Tolerability of AD 337 in the Treatment of Fibromyalgia in Female Subjects.

Year: 2007
Type: Musculoskeletal
Phase: II
Indication: Fibromyalgia

A Randomized, Observer-Blind with Single-Blind Booster, Multi Centre, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult and Elderly Subjects.

Year: 2013
Type: Vaccine
Phase: II
Indication: Healthy

CONNECT WITH US

CONTACT US

Disclaimer: This website provides general information only; it should not be construed as medical advice nor does it replace the need to seek medical advice from a qualified medical professional. To the maximum extent permitted by law, Genesis Research Services Pty Ltd will not be liable in any way for any injury, loss or damage suffered by you through accessing or using the information on this website. View our Privacy Policy. You are strictly prohibited from downloading, copying, altering, modifying, distributing, adapting, modifying and/or re-transmitting any or all of the content on the website for any commercial use without the written consent of Genesis Research Services.